Plain English Summary
Background and study aims
Annually, 6,000 people in the UK are referred for fitting of an artificial lower leg (known as a prosthesis) after the surgical removal of their limb (lower-limb amputation). These are mostly patients over 50 years and usually have diabetes and/or blood vessel (vascular) problems. Older patients are often prescribed standard foot-ankle prostheses which are rigid at the “ankle”, unlike those often given to younger people which can adjust to slopes and stairs. It is unknown which is the best prosthesis for older patients. The aim of this study is to see whether it is possible to do a large study comparing the standard foot-ankle prosthesis to a new version, by first carrying out a smaller study.
Who can participate?
Patients aged over 50 with a below-knee amputation because of vascular problems and who find walking difficult
What does the study involve?
Participants are randomly allocated into one of two groups to wear either their existing prosthesis or a new prosthesis for 12 weeks. One-to-one interviews are held to ask patients how they felt about participating in the study. The researchers measure how far patients can walk, how long they wear their prosthesis daily, and ask them to score their pain, health and well-being. This is done with questionnaires, simple exercise tests and a wearable device which measures activity.
What are the possible benefits and risks of participating?
Participants may not directly benefit from this study but taking part could help build up the evidence about how beneficial the new prosthesis is compared to standard prostheses. No risks are expected, but participants in the new prosthesis group may find that it can take them some time to adjust to the new prosthetic, therefore they could slip or stumble as they adjust to it.
Where is the study run from?
1. Hull & East Yorkshire NHS Trust (UK)
2. Nottingham University Hospitals NHS Trust (UK)
When is the study starting and how long is it expected to run for?
April 2018 to March 2020
Who is funding the study?
National Institute for Health Research (NIHR) (UK)
Who is the main contact?
Dr Natasha Mitchell
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
37815
Study information
Scientific title
STEPFORWARD: Patient acceptability of a novel prosthetic device: a randomised feasibility study in older patients with vascular-related amputations and multimorbidities
Acronym
STEPFORWARD
Study hypothesis
To assess the feasibility of conducting a future, full scale randomised controlled trial into the effectiveness and cost-effectiveness of a novel prosthesis for older patients with vascular-related amputations and other health issues compared to a standard prosthesis.
Ethics approval
Yorkshire & the Humber - Leeds West, 09/03/2018, ref: 18/YH/0089
Study design
Randomised; Both; Design type: Treatment, Process of Care, Device, Rehabilitation, Qualitative
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Disorder of arteries and arterioles, unspecified
Intervention
Multi-centre, randomised controlled, open feasibility study, using a 1:1 randomisation ratio, patients will be block randomised, stratified by prosthetics centre.
The study will look at the randomisation process, recruitment and whether patients found the study processes acceptable. Over two years, the trialists want to recruit 90 older people with a below-knee amputation because of vascular problems and who find walking difficult. They will invite patients from three prosthetics centres across England to participate and they will be placed randomly into one of two groups by a computer: wearing 1) their existing prosthesis or 2) a new prosthesis for 12 weeks. There will be one-to-one interviews to ask how patients felt about participating in the study. The trialists will measure how far patients can walk, how long they wear their prosthesis daily, and ask them to score their pain, health and well-being. They will do this with questionnaires, simple exercise tests and a wearable device which measures activity.
Intervention type
Other
Phase
Drug names
Primary outcome measure
The feasibility of conducting a future, full scale RCT into the effectiveness and cost-effectiveness of a novel prosthesis for older patients with vascular-related amputations and other health issues compared to a standard rigid prosthesis. This will be assessed based on whether:
1. Study consent/retention rates and proposed sample sizes indicate recruitment for the full-scale RCT is plausible within a 24-month period
2. Outcome measures and fidelity evaluation data are successfully collected
3. There are no significant barriers to delivery of the trial identified by participants or recruiting centres
Secondary outcome measures
1. Patient recruitment rate
2. Barriers to recruitment, how these might be overcome from the perspective of patients, and the most important outcomes to them
3. The acceptability of the study procedures to both participants and recruiting centres
4. Patient use of NHS resources over the study period related to the research
5. Identify a primary outcome measure(s) for a future main trial (if feasibility is established)
6. The completeness of follow-up to establish how feasible it is to collect patient-reported outcome measures including data related to patient function, health status, adverse events and use of the NHS
7. Day-to-day use of the prosthesis in both groups and measure normal physical activity through the use of wearable technologies (activity monitors)
Overall trial start date
01/04/2018
Overall trial end date
31/03/2020
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
Current inclusion criteria as of 10/05/2018:
1. Aged over 50 years
2. Has a unilateral amputation
3. Has a below-knee amputation only
4. Has an amputation due to vascular reasons (diabetes, peripheral vascular disease), neurological disorders (i.e. diabetic neuropathy) or life-limiting illness (i.e. tumour, cancer)
5. Is categorised as 'limited mobility’ (K2 classification or SIGAM mobility grade C or D)
6. Is currently using a standard prosthetic foot-ankle (e.g. SACH, uniaxial, multiflex or other K1/K2 feet) that does not adjust to sloped surfaces and is not self-aligning
7. Has been using a prosthesis for at least 12 months, with the same socket for a minimum of 3 months
8. Has had a stable residual limb for at least 3 months (i.e. stable in volume and without cuts or wounds; daily management of volume with socks and liners is acceptable)
9. Is willing to trial a new prosthesis for a 12-week period (if allocated to intervention arm)
10. Is able to self-complete the English language outcome measure tools (or complete with assistance)
11. Is able to follow the detailed verbal instructions required for the functional/clinical tests
12. Is able to provide written informed consent
Previous inclusion criteria:
1. Aged over 50 years
2. Has a unilateral amputation
3. Has a below knee amputation only
4. Has an amputation due to vascular reasons (diabetes, peripheral vascular disease), neurological disorders (i.e., diabetic neuropathy) or life-limiting illness (i.e. tumour, cancer)
5. Is categorised as ‘limited mobility’ (K2 classification or SIGAM mobility grade C or D)
6. Is currently using a standard prosthetic foot-ankle (e.g., SACH, uniaxial, multiflex or other K1/K2 feet) that does not adjust to sloped surfaces and is not self-aligning
7. Has been using a prosthesis for at least 12 months
8. Has had a stable residual limb for at least 3 months (i.e. stable in volume and without cuts or wounds)
9. Is willing to trial a new prosthesis for a 12-week period (if allocated to intervention arm)
10. Is able to self-complete the English language outcome measure tools (or complete with assistance)
11. Is able to follow the detailed verbal instructions required for the functional/clinical tests
12. Is willing to have their GP informed of their involvement in the study
13. Is able to provide written informed consent
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Planned Sample Size: 90; UK Sample Size: 90
Participant exclusion criteria
A patient will be excluded for the following reasons:
1. Has contraindications of wearing their current prosthesis (e.g., open wound, infection)
2. Has contraindications of wearing the novel prosthesis according to manufacturer’s instructions (i.e., a long residual limb - intact side measurement from mid patella tendon to ground minus the socket measurement from mid patella tendon to distal end of socket female-pyramid-adaptor should be at least 115mm)
3. Has had a recent cerebrovascular event, such as a stroke
4. Has a disease that severely affects their memory, such as dementia or Alzheimer’s
Recruitment start date
01/05/2018
Recruitment end date
31/08/2019
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Hull & East Yorkshire NHS Trust
HU16 5JQ
United Kingdom
Trial participating centre
Nottingham University Hospitals NHS Trust
NG5 1PJ
United Kingdom
Trial participating centre
Lancashire Teaching Hospitals NHS Foundation Trust
PR2 9HT
United Kingdom
Funders
Funder type
Government
Funder name
NIHR Central Commissioning Facility (CCF); Grant Codes: PB-PG-0816-20029
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Planned publication in a high-impact peer reviewed journal.
IPD sharing statement
The data sharing plans for the current study are unknown and will be made available at a later date.
Intention to publish date
31/03/2021
Participant level data
To be made available at a later date
Basic results (scientific)
Publication list